Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Shares of Gilead Sciences are down 0.22% at $151.03. The company is worth $187.27B, number 81 out of 300 on our list.
Over the past 52 weeks it has traded between $105.84 and $154.51, so it sits 2.3% below the top of that range. Holders are ahead 35.4% over twelve months, and up 20.7% across the last three months.
On the chart it holds above both the 50-day ($140.65) and 200-day ($134.81) moving averages; RSI is 67, and the last 30 sessions moved at roughly 24% annualized volatility.
In the quarter ended Jun 2026 the company brought in $7.80B of revenue, up 10.2% from a year earlier, and a net loss of $10.50B.
19 analysts follow the stock and the average call is "buy". The mean target, $163.12, sits 8.0% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Gilead Sciences makes HIV treatments, liver disease drugs and cancer therapies, and sells the HIV prevention drug Yeztugo.
What tends to move it. The durability of its HIV franchise and progress on long-acting prevention drugs are the main storylines.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +2.1% | Bullish |
| Price vs 50-day average | +7.4% | Bullish |
| Price vs 200-day average | +12.0% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 66.6 | Bullish |
| MACD (12,26,9) | 2.88 | Bullish |
| Bollinger band position | 77% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 2:00 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
Quarter 2026/Q2
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 1st percentile, 5-year average 93.7x
Near the top of its 5-year range · 99th percentile, 5-year average 5.6x
#5025 of 5303 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 96th percentile, 5-year average 4.0x
#4016 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$38.38M (4 inflow days, 16 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 4.8% a year.
$151.03 is the latest print for GILD, a move of -0.22% against yesterday's close of $151.37. Today's low and high so far: $149.69 and $152.97.
Equity value comes to $187.27B at the current price. By that measure it is number 81 of the 300 names in our coverage.
The year's floor is $105.84 and the ceiling $154.51. Shares are 2.3% away from that ceiling.
It does. Payouts over the past twelve months work out to a 2.13% yield; the latest ex-dividend date was September 15, 2026.
Of 19 analysts, 89% say buy, 11% hold and 0% sell. Price targets average $163.12, with the most cautious at $130.00 and the most optimistic at $177.00.
Gilead Sciences makes HIV treatments, liver disease drugs and cancer therapies, and sells the HIV prevention drug Yeztugo.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.